In vitro , FN-CNPs reduce lipid peroxidation and ROS levels while restoring GPX4, FSP1, and ACSL3 expression in IL-1-stimulated chondrocytes
Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record
Anatomical registration To assess the consistency of MRS voxel tissue composition, the voxels were coregistered to the T1-weighted image and segmented using the Gannet CoRegStandAlone function 64 , which calls SPM12 (ref
Aging 4 , 13841393 (2024)
Finally, the enzyme dehydroascorbate reductase (DHAR) links glutathione oxidation to ascorbate regeneration, though this reaction can also occur chemically at significant but lower rates (Foyer and Mullineaux, 1998)
